基于Si的剂对酒精宿醉和急性乙醇过量引起的肝损伤的影响
Yoshihisa Koyama1,2, Xin Ye1, Yuki Kobayashi3
1Department of Neuroscience and Cell Biology, Graduate School of Medicine, The University of Osaka, Osaka, 565-0871, Japan.
Biochemistry and biophysics reports
|November 17, 2025
概括
一种基于的新型药物通过减少氧化应激和帮助乙醇代谢,有效地治疗酒精宿醉和肝损伤. 这种药物对未来对抗过度饮酒效应的治疗应用有前途.
科学领域:
- 生物化学 生物化学
- 毒理学 毒理学 毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 过度饮酒会导致宿醉症状和肝损伤.
- 目前对与酒精有关的问题的治疗方法有限.
- 气显示出减轻酒精引起的伤害的潜力.
研究的目的:
- 评估一种基于的药物,用于治疗酒精宿醉症状和乙醇引起的肝损伤.
- 评估该药物对小鼠运动障碍和肝脏病理的影响.
主要方法:
- 基剂的口服给急性过量服用的小鼠模型.
- 评估运动活动,行为表现和运动协调.
- 肝脏组织的形态分析和测量化脱水酶激活和抗氧化能力.
主要成果:
- 这种基于的药物减轻了酒精引起的自发活动,行为表现和运动协调的减少.
- 在接受治疗的组中,观察到乙醇诱导的肝损伤明显减少.
- 脱水酶激活正常化,而抗氧化能力在治疗组中略有增加,尽管在统计学上并不显著.
结论:
- 这种基于的药物可以缓解宿醉相关的运动障碍和肝损伤.
- 它通过减少氧化应激和促进乙醇代谢来起作用.
- 这种药物对酒精宿醉和肝损伤具有潜在的治疗策略.
相关概念视频
CNS Depressants: Alcohol and Nicotine
1.0K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.0K
Depressants
370
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
370
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
244
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
244
Acid Halides to Esters: Alcoholysis
3.9K
Alcoholysis is a nucleophilic acyl substitution reaction in which an alcohol functions as a nucleophile. Acid halides react with alcohol to produce esters. The mechanism proceeds in three steps:
3.9K
Anticholinesterase Agents: Poisoning and Treatment
1.5K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.5K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
208
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
208


